Dan O'Day (AP Images)
Gilead CEO Dan O'Day's $21B M&A deal to buy Immunomedics gets some harsh reviews
After a wild, 4-year roller coaster ride, ImmunoMedics $IMMU is getting its fairy-tale ending after all.
Sunday evening Gilead $GILD put the weekend rumors to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
